XNASSGMT
Market cap170mUSD
Jan 07, Last price
5.57USD
1D
-17.85%
1Q
33.89%
IPO
-65.08%
Name
Sagimet Biosciences Inc
Chart & Performance
P/E
—
P/S
85.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
Net income
-28m
L-8.60%
CFO
-24m
L-2.96%
Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,000 | ||||
Cost of revenue | 32,740 | 31,185 | |||
Unusual Expense (Income) | |||||
NOPBT | (30,740) | (31,185) | |||
NOPBT Margin | |||||
Operating Taxes | (31,608) | ||||
Tax Rate | |||||
NOPAT | (30,740) | 423 | |||
Net income | (27,876) -8.60% | (30,499) 24.78% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 89,679 | 12 | |||
BB yield | -158.18% | ||||
| Debt | |||||
Debt current | 130 | 133 | |||
Long-term debt | 65 | 289 | |||
Deferred revenue | |||||
Other long-term liabilities | 214,624 | ||||
Net debt | (94,702) | (31,923) | |||
| Cash flow | |||||
Cash from operating activities | (23,766) | (24,490) | |||
CAPEX | |||||
Cash from investing activities | 12,580 | (32,010) | |||
Cash from financing activities | 86,167 | (73) | |||
FCF | (30,601) | 553 | |||
| Balance | |||||
Cash | 94,897 | 32,345 | |||
Long term investments | |||||
Excess cash | 94,797 | 32,345 | |||
Stockholders' equity | (249,712) | (7,331) | |||
Invested Capital | 340,907 | 35,216 | |||
ROIC | 0.30% | ||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 10,460 | 22,174 | |||
Price | 5.42 | ||||
Market cap | 56,695 | ||||
EV | (38,007) | ||||
EBITDA | (30,740) | (31,055) | |||
EV/EBITDA | 1.24 | ||||
Interest | |||||
Interest/NOPBT | |||||